Database

PharmaInformatic

Solution provided
Technology
Supplier identity
General description

Expert system IMPACT-F calculates oral bioavailability of your future drug candidates in humans. PharmaInformatic was founded in 2004 and provides ADME knowledge bases and predictive tools (expert systems) to improve drug discovery and development. PACT-F is the largest and most annotated knowledge base on bioavailability of drugs worldwide. The expert system IMPACT-F calculates human oral bioavailability much more precisely compared to preclinical animal trials.

 

Type of Supplier
IT/ Software Solutions ProviderClinical Trials Solutions Provider
Sector of activity
  • Bioinformatics
  • Drug Discovery / Research & Development
  • Infectious diseases
  • Software / Modelling
  • Translational medecine
Region
State of Lower Saxony, DE
Regional access broker
  • Annika Buchholz, BiomeTI e.V.
Activity description
The 3 top equipments available

 

Preclinical And Clinical Trials Knowledge Base on Bioavailability (PACT-F):

PACT-F contains experimental bioavailability results of clinical trials in humans and preclinical trials in animals. The results and conditions of those trials have been taken manually from reliable scientific publications. PACT-F contains the knowledge from more than 5000 scientific research articles related to bioavailability.

The development of PACT-F commenced in 2005. PACT-F is now the largest knowledge base on bioavailability worldwide. It contains 8296 records, which describe in detail the results of clinical trials in humans and preclinical trials in animals.

PACT-F is extensively annotated: up to 17 fields describe in detail the results and conditions of each trial, such as route of administration, species investigated, drug formulation, coadministration of drug, feeding condition, age and gender of the subjects involved, dosing scheme, genetic differences, experimental and analytical procedure, method of calculation and state of health.

Every record in PACT-F contains the chemical structure of the compound that was used in the specific trial. This enables scientists to build relationships between drug structures and their oral bioavailability.

 

Expert Systems:

PharmaInformatic´s expert systems help to identify and prioritise promising drug candidates for clinical trials in humans. They select compounds which display a high probability of becoming a successful drug:

 

IMPACT-F calculates human oral bioavailability of drug candidates. The performance and quality of those models, validated with large, independent and diverse set of drugs, was shown to be remarkably better compared to animal trials, see details.


MolScore-Antibiotics detects antibacterial drug candidates. The expert system recognises structural patterns of every type of antibiotics, even new antibiotic substances with unknown mechanism of action which are now in clinical trials.


MolScore-Antivirals detects antiviral drug candidates. The expert system combines different strategies of drug research, so that structural patterns of virus-specific and target-specific inhibitors will be recognised.


MolScore-Drugs helps to identify and prioritise promising drug candidates with the maximum possibility of success in human trials. The expert system prioritises drug candidates in multiple therapeutic areas.
 

Know-how, expertise available

Oral bioavailability is one of the most important properties in drug development. A high oral bioavailability reduces the amount of an administered drug necessary to achieve a desired pharmacological effect and therefore could reduce the risk of side-effects and toxicity. A poor oral bioavailability can result in low efficacy and higher inter-individual variability and therefore can lead to unpredictable response to a drug.

Low oral bioavailability in clinical trials is a major reason for drug candidates failing to reach the market. Therefore, several strategies have been developed to estimate human oral bioavailability of novel drug candidates.

PharmaInformatic was founded in 2004 by Dr Wolfgang Boomgaarden. He has invented several drug design and virtual screening products, which have been successfully used in pharmaceutical research. Before he founded the company, he worked as a professor in bioinformatics at the University of Applied Science in Emden, Germany.

 

Possibilities of partnership

IMPACT-F estimates oral bioavailability of novel drug candidates in humans. The expert system is composed of several reliable models to predict oral bioavailability in humans. The performance and quality of these models, validated with large, independent and diverse sets of drugs, was shown to be remarkably better compared to preclinical trials in animals.

IMPACT-F was validated with novel drug candidates coming from different therapeutic areas such as cancer, inflammation, infectious disease, CNS, gastrointestinal and cardiovascular diseases. IMPACT-F calculates oral bioavailability in humans much more precisely compared to preclinical animal trials.

The expert system can forecast oral bioavailability of novel drugs reliable. Bioavailability predictions of  IMPACT-F were as accurate as the common deviation between individual humans taking part in the same clinical trial (inter-subject variability in humans). The expert system is now available for licensing.

 

PACT-F is the fundamental knowledge base on oral bioavailability which allows to

  • analyse the factors which influence bioavailability
  • predict oral bioavailability in humans
  • select and optimise drug candidates for clinical trials

PACT-F is a structure-based knowledge base. This enables scientists to build relationships between structures and bioavailability (QSBR), such as which molecular patterns increase or decrease the bioavailability of a drug, either generally in all organisms or only in some specific species.

PACT-F is now available for licensing. For licensing and pricing information, please contact us.

 

Services provided

Prediction-Service:
Several expert systems are ready to use. They help to identify and prioritise promising drug candidates for clinical trials in humans.

IMPACT-F is a novel expert system, which predicts human oral bioavailability of future drugs. The expert system was launched in May 2013.

To use our prediction-service, please contact us.

 

Follow us on Twitter:
https://twitter.com/PharmaInformati

Training and Staff possibilities
No
Contact information
Name
Wolfgang
Surname
Boomgaarden
Function
Founder and CEO
Phone number
+49-4921-993360
Address
Friesenstraße 36
26721  Emden
Germany